AVITA Medical Q3 revenue falls 13% YoY to $17.1M; lowers FY2025 revenue guidance to $70-74M

AVITA Medical, Inc.

2025-Q3 EPS reported -$1.37 revenue$53,995,000

Net loss improved to $13.2M ($0.46 loss per share) from $16.2M in Q3 2024; cash use cut to $6.2M.
Full-year 2025 revenue guidance lowered to $70-74M from prior $76-81M, citing MAC reimbursement headwinds.
Sixth amendment to OrbiMed credit agreement adds $500K to principal, resets Q4 2025 revenue covenant to $70M.
RECELL GO received CE Mark under EU MDR; launch to begin in Germany, Italy, and UK.
Operating expenses down 24% YoY to $23.0M as part of cost discipline; cash $23.3M at Sept 30.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.